Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4660MR)

This product GTTS-WQ4660MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4660MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13289MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ13088MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ14230MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ6157MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ12003MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ11494MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ15223MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ1267MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW